Racura Presents Bisantrene MYC Data at FCS 2026
Released
Released
Announcement PDF
Racura Oncology Ltd | ABN 61 149 318 749 | L36 1 Macquarie Place Sydney NSW 2000 Australia
+61 2 8051 3043 | info@racuraoncology.com | www.racuraoncology.com 1
ASXAnnouncement
Racura Presents Bisantrene MYC Data
at FCS 2026 Conference
§ Racura presenting at the Frontiers in Cancer Science (FCS) 2026 Conference being held in
Singapore from 11–13 November 2026
§ Preclinical data presented show that (E,E)-bisantrene is the active isomer stabilising the MYC
G-quadruplex (G4) structure, leading to reduced MYC gene expression and activity
§ The findings support the use of RC220 in the EMILI, HARNESS and CPACS clinical programs
12 November 2026
Racura Oncology Limited (“Racura” or the “Company”) is pleased to announce that new preclinical data on
the ability of (E,E)-bisantrene to inhibit MYC gene transcription are being presented as a poster at the
Frontiers in Cancer Science (FCS) 2026 Conference in Singapore on 12 November 2026. The data show
that (E,E)-bisantrene is the major isomer (molecular form) of bisantrene able to stabilise the MYC promoter
G-quadruplex and inhibit MYC gene transcription and reduce MYC protein levels. In these preclinical
studies, light exposure converted (E,E)-bisantrene into less active isomers, which resulted in significantly
less MYC G-quadruplex stabilisation and inhibition of MYC gene expression and activity.
These findings build on the MYC gene expression inhibition data for (E,E)-bisantrene presented at the 2026
American Association for Cancer Research (AACR) Annual Meeting (ASX Announcement: 22 April 2026)
and match the lower cancer cell killing activity observed from (E,E)-bisantrene after it is exposed to light.
Racura continues to investigate this mechanism through its ongoing research collaboration with Purdue
University (ASX Announcement: 26 March 2026).
A copy of the poster entitled “Light-Induced Isomerization Attenuates (E,E)-Bisantrene G-Quadruplex
Binding and MYC Silencing” is attached to this announcement.
Racura CEO and MD, Dr Daniel Tillett, commented: “These data show that (E,E)-bisantrene is the form that
stabilises G-quadruplex structures and inhibits MYC gene expression. Bisantrene can exist as several
isomers, and confirming that the (E,E)-isomer is the active form supports our development of RC220 as a
proprietary formulation of (E,E)-bisantrene. While these are preclinical findings, they add to the growing
body of evidence for the MYC-directed mechanism of action of RC220.”
-ENDS-
(E,E)-bisantrene undergoes photoisomerization in solution to give mixtures of (E,E)-, (E,Z)- and (Z,Z)-bisantrene (postulated). Pure (E,Z)- and (Z,Z)-isomers
cannot be isolated, so activity was compared using HPLC-characterized isomer mixtures. (E,E)-bisantrene is the most active isomer. Mixtures with less (E,E)-
bisantrene showed decreased MYC G4 stabilization, reduced ability to suppress MYC gene and protein expression and weaker reduction of cancer cell viability.
Preventing (E,E)-bisantrene photoisomerization is therefore critical in clinical studies (CPACS: Phase 1 RC220 with doxorubicin in advanced solid tumors
[ClinicalTrials.gov ID: NCT06815575]; HARNESS-1: Phase 1 RC220 with osimertinib in EGFR-mutant non-small cell lung cancer [ANZCTR ID:
ACTRN12626000325303]; and EMILI: Phase 2b/3 RC220 monotherapy in relapsed/refractory acute myeloid leukemia [registration pending]).
Emily Ryan1,2, Peter Cuthbertson1, Chelsea Penney1, Nehad S. El Salamouni2, Qiang Zhu2, Haibo Yu2, Sumit Sahni1, Daniel Tillett1, Michael J. Kelso1
1
Racura Oncology Ltd, Sydney, Australia 2
University of Wollongong, Wollongong, Australia
CONCLUSION
BACKGROUND METHODS
(E,E)-Bisantrene Photoisomerization
RESULTS
MYC G-Quadruplex Stabilization
Light-Induced Isomerization Attenuates
(E,E)-Bisantrene G-Quadruplex Binding & MYC Silencing
G-quadruplexes (G4) are non-
canonical secondary structures
enriched within promoter regions of
key oncogenes, such as MYC. G4s
can regulate the expression of these
oncogenes (Fig 1).
(E,E)-bisantrene contains two
identical (E)-hydrazone groups that
can potentially undergo
isomerization.
0
20
40
60
80 68.99 °C
60.64 °C
68.28 °C
33.61 °C
Melting
Temperature
(°C)
✱✱✱✱
✱✱✱✱
ns
✱ ✱
MYC (5 μM)
100% (E,E)
62% (E,E)
+
16 μM
10 μM
10 μM
+ + +
-
- -
- -
Molecular Dynamics Simulations
Cell Viability
MYC Gene and Protein Suppression
MYC
GAPDH
100%(E,E)-Bis ~60%(E,E)-Bis
1 2 4 6 24
~40%(E,E)-Bis
1 2 4 6 24
Unquantifiable
0
MYC
GAPDH
(E,E)-bisantrene was exposed to 440 nm (blue) LED light and the amount of
(E,E)-bisantrene remaining was quantified by HPLC.
Molecular dynamics simulations (MM/GBSA method) predicted the binding
sites and estimated affinity of (E,E)- and (E,Z)-bisantrene isomers for MYC G4.
Stabilization of MYC G4 (TGAGGGTGGGTAGGGTGGGTAA) by (E,E)-bisantrene
was compared to an isomer mixture containing 62% (E,E)-bisantrene using
circular dichroism (CD). Melting curves were monitored at 265 nm and
melting temperatures determined.
MDA-MB-231 breast cancer cells were treated with (E,E)-bisantrene or
isomer mixtures. MYC gene and protein expression was assessed by qPCR
and western blotting. Cell viability was measured by ATPlite luminescence
assay.
CD spectroscopy confirmed (E,E)-
bisantrene stabilizes MYC G4. Isomer
mixtures containing 62% (E,E)
stabilized MYC G4, but significantly
less than 100% (E,E) (Fig 5).
Increasing the isomer mixture
concentration to 16 µM (i.e. to create
an equimolar amount of (E,E) (10 µM)
as 100% (E,E)) restored stabilization
to the original level (Fig 5).
This indicates (E,E)-bisantrene is the
isomer that most strongly stabilizes
MYC G4.
Fig 1: MYC gene expression is regulated by G-
quadruplexes (G4) in the promoter region.
This study was funded by Racura Oncology • www.racuraoncology.com • Contact: Emily Ryan (emily.ryan@racuraoncology.com) • ER, PC, CP, SS, DT and MJK are employees of Racura Oncology.
5 10
0
200
400
600
800
Retention Time (min)
Absorbance
(263nm)(mAU)
*
*
*
#
#
*
#
= (E,E)
= (E,Z)
0 h Blue
0.25 h Blue
1 h Blue
4 h Blue
= (Z,Z)
&
&
Fig 3: HPLC chromatograms of
isomer mixtures (10 mM)
generated by exposure to 440 nm
LED light for 0, 0.25, 1 or 4 h.
Fig 2: Interconversion of (E,E)-, (E,Z)- and (Z,Z)-
bisantrene (postulated) in solution is triggered by light
(hν) or thermal energy (Δ).
(E,E) (E,Z) (Z,Z)
Fig 6: MYC expression in MDA-MB-231 breast
cancer cells after treatment (2 h) with (E,E)-
bisantrene and isomer mixtures (≤10,000 nM).
Fig 5: Melting temperature of MYC G4 (5 µM) ±
100% (E,E)-bisantrene (10 µM) or isomer mix
containing 62% (E,E)-bisantrene at 10 µM or
16 µM (molar equivalent of 10 µM (E,E)).
Fig 7: (A) Time course of MYC protein levels in MDA-MB-231 breast cancer cells after
treatment with (E,E)-bisantrene or isomer mixtures (200 nM). (B) Densitometry of MYC protein,
relative to control. Two-way ANOVA with Tukey’s multiple comparisons.
Fig 8: Cell viability of MDA-MB-231 breast cancer cells after
72 h treatment with (E,E)-bisantrene or isomer mixtures
(≤10,000 nM).
0 1 2 4 6 24
0.0
0.2
0.4
0.6
0.8
1.0
1.2
100% (E,E)-bisantrene
Time (h)
MYC
Expression
(Relative
to
Control)
*
**
**
***
0 1 2 4 6 24
0.0
0.2
0.4
0.6
0.8
1.0
1.2
~60% (E,E)-bisantrene
Time (h)
MYC
Expression
(Relative
to
Control)
**
*
*
*
0 1 2 4 6 24
0.0
0.2
0.4
0.6
0.8
1.0
1.2
~40% (E,E)-bisantrene
Time (h)
MYC
Expression
(Relative
to
Control)
*
*
0 1 2 4 6 24
0.0
0.2
0.4
0.6
0.8
1.0
1.2
Unquantifiable
(E,E)-bisantrene
Time (h)
MYC
Expression
(Relative
to
Control)
qPCR and western blotting
confirmed (E,E)-bisantrene
suppresses MYC gene and
protein expression (Figs 6 & 7).
Suppression of MYC gene and
protein expression was
significantly reduced by
decreasing the (E,E)-bisantrene
content in isomeric mixtures
(Figs 6 & 7).
Cell viability assays
showed MDA-MB-231
breast cancer cells were
sensitive to 100% (E,E)-
bisantrene (IC50 266
nM, Fig 8).
Decreasing the (E,E)-
bisantrene content in
isomeric mixtures
raised the IC50 to 310–
825 nM, indicating
reduced
antiproliferative activity
(Fig 8).
1 10 100 1000 10000
0
20
40
60
80
100
120
Concentration (nM)
Cell
Viability
(%)
100% (E,E)
~60% (E,E)
~40% (E,E)
Unquantifiable
IC50 ± SEM
266 ± 51 nM
310 ± 26 nM
483 ± 84 nM
825 ± 166 nM
This study evaluated the impact of light-induced isomerization
(photoisomerization) of (E,E)-bisantrene on MYC promoter region G4 binding,
MYC gene and protein suppression and cancer cell viability.
Fig 4: Representative poses of one molecule of (A) (E,E)-
bisantrene or (B) (E,Z)-bisantrene (orange sticks) bound to
MYC G4. 5′ and 3′ ends of the DNA chain are indicated by red
and blue spheres, respectively. K+ ions are indicated by
purple spheres.
Molecular dynamics
simulations predicted a
trend toward higher
affinity for (E,E)-
bisantrene over (E,Z)-
bisantrene at the top G-
tetrad binding site on
MYC G4 (Fig 4).
ΔG = −48.1 ± 9.4 kcal/mol ΔG = −42.1 ± 5.4 kcal/mol
Exposure to 440 nm light photoisomerized (E,E)-bisantrene solutions to (E,Z)-
and (Z,Z)-bisantrene (postulated) (Fig 2). Exposure for 0.25, 1 or 4 h reduced
the (E,E)-bisantrene content to ~60%, ~40% and an unquantifiable level,
respectively (broad unresolved hump peak at 4 h postulated as oligomerized
(Z,Z)-isomer) (Fig 3).
10 100 1000 10000
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
Concentration (nM)
Relative
MYC
Expression
100% (E,E)
~60% (E,E)
~40% (E,E)
Unquantifiable
EC50 ± SEM
277 ± 47 nM
514 ± 93 nM
721 ± 112 nM
1166 ± 68 nM
ns
✱
✱✱✱
B
A
Racura Oncology Ltd | ABN 61 149 318 749 | L36 1 Macquarie Place Sydney NSW 2000 Australia
+61 2 8051 3043 | info@racuraoncology.com | www.racuraoncology.com 2
About Racura Oncology
Racura Oncology (ASX: RAC) is a late-stage clinical biopharmaceutical company with a mission to silence
cancer.
Racura’s lead asset, (E,E)-bisantrene, is a clinically derisked small-molecule anticancer agent that
primarily acts by stabilising G4-DNA and RNA structures, driving potent inhibition of c-MYC gene
expression, a key cancer gene dysregulated in up to 70% of all cancers. Bisantrene has shown therapeutic
activity in cancer patients and has a well-characterised safety profile. Racura’s discoveries have supported
composition-of-matter IP filings that, if granted, could provide up to 20 years of patent protection for (E,E)-
bisantrene.
Racura is advancing RC220, its proprietary formulation of (E,E)-bisantrene, to address significant unmet
need across multiple MYC-driven oncology indications. The Company’s clinical programs include the EMILI
Phase 2b/3 trial in acute myeloid leukaemia, the HARNESS Phase 1 trial in combination with osimertinib
for EGFRm NSCLC, and the CPACS Phase 1 trial in combination with doxorubicin, where Racura aims to
deliver both anthracycline cardioprotection and enhanced anticancer activity.
Racura has collaborated with Astex, Emory University, Purdue University, MD Anderson Cancer Center,
Sheba Medical Center, University of North Carolina School of Medicine, University of Wollongong, and
University of Newcastle. Racura is actively exploring partnerships, licence agreements, and potential
commercial merger and acquisition opportunities to accelerate global patient access to RC220.
Learn more at www.racuraoncology.com.
If you have any questions on this announcement, or any past Racura Oncology announcements, please
visit the Company’s Interactive Announcements page.
Racura encourages all investors to go paperless by registering their details with the Company’s share
registry, Automic Registry Services, at www.automicgroup.com.au.
Release authorised by Media Contact
Daniel Tillett, CEO/MD Cherie Hartley +61 418 737 020
info@racuraoncology.com cherie.hartley@irdepartment.com.au
Share your feedback
Discover